The FDA supports exploring with Orexigen Therapeutics (OREX +4.9%) how the firm can speed up its...

|About: Orexigen Therapeutics, Inc. (OREX)|By:, SA News Editor

The FDA supports exploring with Orexigen Therapeutics (OREX +4.9%) how the firm can speed up its application for weight loss pill Contrave. The FDA rejected the drug in January 2011, due to possible heart problems, and asked Orexigen to conduct another study. The company has so far enrolled 7,000 patients and intends to recruit another 9,000 by the year-end. (PR)